Simon J I Sandler1, Anthony A Figaji, P David Adelson. 1. Division of Neurosurgery, School of Child and Adolescent Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Klipfontein Road, Rondebosch, Cape Town, South Africa.
Abstract
INTRODUCTION: The diagnosis, treatment, and prediction of outcome in pediatric traumatic brain injury (TBI) present significant challenges to the treating clinician. Clinical and radiological tools for assessing injury severity and predicting outcome, in particular, lack sensitivity and specificity. In patients with mild TBI, often there is uncertainty about which patients should undergo radiological imaging and who is at risk for long term neurological sequelae. In severe TBI, often there is uncertainty about which patients will experience secondary insults and what the outcome for individual patients will be. In several other clinical specialties, biomarkers are used to diagnose disease, direct treatment, and prognosticate. However, an ideal biomarker for brain injury has not been found. METHODS: In this review, we examine the various factors that must be taken into account in the search for a reliable biomarker in brain injury. We review the important studies that have investigated common biomarkers of structural brain injury, in particular S100B, neuron-specific enolase, myelin basic protein, and glial fibrillary acid protein. DISCUSSION: The potential uses and limitations of these biomarkers in the context of TBI are discussed.
INTRODUCTION: The diagnosis, treatment, and prediction of outcome in pediatric traumatic brain injury (TBI) present significant challenges to the treating clinician. Clinical and radiological tools for assessing injury severity and predicting outcome, in particular, lack sensitivity and specificity. In patients with mild TBI, often there is uncertainty about which patients should undergo radiological imaging and who is at risk for long term neurological sequelae. In severe TBI, often there is uncertainty about which patients will experience secondary insults and what the outcome for individual patients will be. In several other clinical specialties, biomarkers are used to diagnose disease, direct treatment, and prognosticate. However, an ideal biomarker for brain injury has not been found. METHODS: In this review, we examine the various factors that must be taken into account in the search for a reliable biomarker in brain injury. We review the important studies that have investigated common biomarkers of structural brain injury, in particular S100B, neuron-specific enolase, myelin basic protein, and glial fibrillary acid protein. DISCUSSION: The potential uses and limitations of these biomarkers in the context of TBI are discussed.
Authors: Georgene Hergenroeder; John B Redell; Anthony N Moore; William P Dubinsky; Robert T Funk; John Crommett; Guy L Clifton; Robert Levine; Alex Valadka; Pramod K Dash Journal: J Neurotrauma Date: 2008-02 Impact factor: 5.269
Authors: David O Ajao; Viorela Pop; Joel E Kamper; Arash Adami; Emil Rudobeck; Lei Huang; Roman Vlkolinsky; Richard E Hartman; Stephen Ashwal; André Obenaus; Jérôme Badaut Journal: J Neurotrauma Date: 2012-07-20 Impact factor: 5.269